Argenx Se (ARGX) Other Non-Current Assets (2016 - 2026)
Argenx Se's (ARGX) quarterly Other Non-Current Assets came in at $124.0 million in Q2 2026, down 99.73% on a YoY basis from $46.7 billion in Q2 2025, and up 125.45% quarter-over-quarter from $55.0 million in Q4 2025.
Analysis
Argenx Se (ARGX) Other Non-Current Assets (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Other Non-Current Assets for 11 consecutive years, with $124.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non-Current Assets fell 99.73% year-over-year to $124.0 million; the trailing twelve-month figure through Jun 2026 stood at $124.0 million (down 99.73% YoY), and the FY2025 full-year result was $55.0 million, down 99.87% from the prior year.
- Other Non-Current Assets improved to $124.0 million in Q2 2026 per ARGX's latest filing, from $55.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $46.7 billion in Q2 2025 and bottomed at $34.3 million in Q2 2024.
- Historically, Other Non-Current Assets has averaged $14.5 billion across 5 years, with a median of $55.0 million in 2025.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets slumped 99.9% in 2023, then soared 136097.34% in 2025.
- Over 5 years, Other Non-Current Assets stood at $40.9 billion in 2022, then plunged by 99.9% to $39.7 million in 2023, then soared by 106785.68% to $42.4 billion in 2024, then sank by 99.87% to $55.0 million in 2025, then jumped by 125.45% to $124.0 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $124.0 million, $55.0 million, and $46.7 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 104.44 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 124.00 Mn |
| Dec 31, 2025 | 55.00 Mn |
| Jun 30, 2025 | 46.68 Bn |
| Dec 31, 2024 | 42.39 Bn |
| Jun 30, 2024 | 34.28 Mn |
| Dec 31, 2023 | 39.66 Mn |
| Jun 30, 2023 | 39.23 Mn |
| Dec 31, 2022 | 40.89 Bn |
| Jun 30, 2022 | 43.10 Mn |
| Dec 31, 2021 | 54.88 Bn |
| Jun 30, 2021 | 1.44 Mn |
| Dec 31, 2020 | 7.61 Bn |
| Jun 30, 2020 | 696,122.80 |
| Dec 31, 2019 | 3.57 Bn |
| Jun 30, 2019 | 400,015.52 |
| Dec 31, 2018 | 287,631.90 |
| Jun 30, 2018 | 313,875.88 |
| Dec 31, 2017 | 147,179.07 |
| Jun 30, 2017 | 1.86 Mn |
| Dec 31, 2016 | 1.24 Mn |